3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma CNMD

CONMED Corporation

CNMD NYSE US2074101013 Biotech & Pharma

Stock factsheet

TickerCNMD
ExchangeNYSE
ISINUS2074101013
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 1,39 Mrd. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

CONMED is a medical technology company that develops and markets surgical devices and consumables for minimally invasive surgery. Its core areas are arthroscopy, laparoscopy, electrosurgery and sports medicine. The company supplies hospitals and ambulatory surgical centres worldwide.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
CONMED CorporationCNMD NYSE1,39 Mrd. USD
ArriVent BioPharma, Inc. AVBPNASDAQ 1,39 Mrd. USD
Xeris Biopharma Holdings, Inc. XERSNASDAQ 1,39 Mrd. USD
Monte Rosa Therapeutics, Inc. GLUENASDAQ 1,40 Mrd. USD
Perrigo Company plc PRGONYSE 1,40 Mrd. USD
MoonLake Immunotherapeutics MLTXNASDAQ 1,36 Mrd. USD
Anbio Biotechnology NNNNNASDAQ 1,42 Mrd. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.